NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
69238-1423-06 | 69238-1423 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2017 | In Use | |
69238-1423-01 | 69238-1423 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec. 29, 2017 | In Use | |
00143-9516-01 | 00143-9516 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Jan. 5, 2018 | In Use | |
00143-9517-01 | 00143-9517 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Jan. 5, 2018 | In Use | |
00143-9518-01 | 00143-9518 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Jan. 5, 2018 | In Use | |
43598-0678-11 | 43598-0678 | AZACITIDINE | AZACITIDINE | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Dec. 13, 2017 | In Use | |
16729-0391-30 | 16729-0391 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 24, 2018 | In Use | |
16729-0419-03 | 16729-0419 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 25, 2018 | In Use | |
16729-0423-33 | 16729-0423 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 24, 2018 | In Use | |
63459-0601-06 | 63459-0601 | Arsenic Trioxide | Trisenox | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Dec. 22, 2017 | In Use | |
43598-0392-48 | 43598-0392 | Melphalan Hydrochloride | Melphalan Hydrochloride | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 18, 2017 | In Use | ||
00143-9550-01 | 00143-9550 | Daunorubicin Hydrochloride | Daunorubicin Hydrochloride | 5.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 2, 2018 | In Use | |
00143-9551-10 | 00143-9551 | Daunorubicin Hydrochloride | Daunorubicin Hydrochloride | 5.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 2, 2018 | In Use | |
00143-9275-01 | 00143-9275 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 19, 2018 | In Use | |
00143-9277-01 | 00143-9277 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 19, 2018 | In Use | |
70121-1244-07 | 70121-1244 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Dec. 18, 2017 | In Use | |
00143-9270-01 | 00143-9270 | Floxuridine | Floxuridine | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intra-Arterial | Feb. 15, 2018 | In Use | |
68083-0292-01 | 68083-0292 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 5, 2018 | In Use | |
68083-0293-01 | 68083-0293 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jan. 5, 2018 | In Use | |
47781-0595-07 | 47781-0595 | paclitaxel | Paclitaxel | 300.0 mg/50mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 27, 2017 | In Use | |
70121-1221-01 | 70121-1221 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 19, 2018 | In Use | |
70121-1222-01 | 70121-1222 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 19, 2018 | In Use | |
70121-1223-01 | 70121-1223 | Docetaxel | Docetaxel | 160.0 mg/8mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 19, 2018 | In Use | |
43066-0001-01 | 43066-0001 | docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 19, 2018 | In Use | |
43066-0006-01 | 43066-0006 | docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 19, 2018 | In Use | |
43066-0010-01 | 43066-0010 | docetaxel | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 19, 2018 | In Use | |
43598-0682-35 | 43598-0682 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | March 13, 2018 | In Use | |
43598-0683-25 | 43598-0683 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | March 13, 2018 | In Use | |
68001-0345-36 | 68001-0345 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 16, 2018 | In Use | |
68001-0345-26 | 68001-0345 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 16, 2018 | In Use | |
69488-0003-01 | 69488-0003 | Lutetium Lu 177 dotatate | Lutathera | 10.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Somatostatin Analog | Intravenous | Jan. 26, 2018 | In Use | |
68001-0359-37 | 68001-0359 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 25, 2018 | In Use | |
68001-0348-36 | 68001-0348 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 25, 2018 | In Use | |
68001-0342-34 | 68001-0342 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 25, 2018 | In Use | |
43598-0650-11 | 43598-0650 | Thiotepa | Thiotepa | 15.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | May 4, 2018 | In Use | |
59651-0205-08 | 59651-0205 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 17, 2018 | In Use | |
59651-0205-10 | 59651-0205 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 17, 2018 | In Use | |
59651-0204-10 | 59651-0204 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 17, 2018 | In Use | |
59651-0204-60 | 59651-0204 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 17, 2018 | In Use | |
70121-1240-01 | 70121-1240 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 31, 2018 | In Use | |
70121-1239-01 | 70121-1239 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 31, 2018 | In Use | |
70121-1238-01 | 70121-1238 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 31, 2018 | In Use | |
16729-0332-03 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
16729-0332-05 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
00409-0323-20 | 00409-0323 | BLEOMYCIN | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | April 25, 2018 | In Use | |
76075-0103-01 | 76075-0103 | carfilzomib | KYPROLIS | 10.0 mg/5mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | May 23, 2018 | In Use | |
69097-0368-40 | 69097-0368 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | May 4, 2018 | In Use | |
62856-0712-30 | 62856-0712 | Lenvatinib | Lenvima | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Aug. 15, 2018 | In Use | |
62856-0704-30 | 62856-0704 | Lenvatinib | Lenvima | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Aug. 15, 2018 | In Use | |
00069-0197-30 | 00069-0197 | dacomitinib | Vizimpro | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct. 4, 2018 | In Use | |
00069-2299-30 | 00069-2299 | dacomitinib | Vizimpro | 45.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct. 4, 2018 | In Use | |
00069-0296-30 | 00069-0296 | talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct. 26, 2018 | In Use | |
00069-1195-30 | 00069-1195 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct. 26, 2018 | In Use | |
00069-0227-01 | 00069-0227 | Lorlatinib | Lorbrena | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Nov. 19, 2018 | In Use | |
00069-0231-01 | 00069-0231 | Lorlatinib | Lorbrena | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Nov. 19, 2018 | In Use | |
00069-0298-60 | 00069-0298 | Glasdegib | Daurismo | 25.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec. 10, 2018 | In Use | |
00069-1531-30 | 00069-1531 | Glasdegib | Daurismo | 100.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec. 10, 2018 | In Use | |
70255-0010-02 | 70255-0010 | BINIMETINIB | MEKTOVI | 15.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | June 27, 2018 | In Use | |
70255-0010-03 | 70255-0010 | BINIMETINIB | MEKTOVI | 15.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | June 27, 2018 | In Use | |
71777-0390-01 | 71777-0390 | LAROTRECTINIB | VITRAKVI | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Nov. 26, 2018 | In Use | |
71777-0391-01 | 71777-0391 | LAROTRECTINIB | VITRAKVI | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Nov. 26, 2018 | In Use | |
71777-0392-01 | 71777-0392 | LAROTRECTINIB | VITRAKVI | 20.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Nov. 26, 2018 | In Use | |
00007-4401-01 | 00007-4401 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 19, 2006 | Dec. 31, 2018 | No Longer Used |
00007-4401-06 | 00007-4401 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 19, 2006 | Dec. 31, 2018 | No Longer Used |
00069-0201-01 | 00069-0201 | Cladribine | Cladribine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Oct. 7, 2011 | Dec. 31, 2017 | No Longer Used |
00002-2980-26 | 00002-2980 | Selpercatinib | RETEVMO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
00002-2980-60 | 00002-2980 | Selpercatinib | RETEVMO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
00002-3977-60 | 00002-3977 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
50242-0091-30 | 50242-0091 | ENTRECTINIB | Rozlytrek | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | In Use | |
50242-0091-86 | 50242-0091 | ENTRECTINIB | Rozlytrek | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | In Use | |
00078-0701-84 | 00078-0701 | Alpelisib | PIQRAY | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
00078-0708-02 | 00078-0708 | Alpelisib | PIQRAY | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
00078-0708-91 | 00078-0708 | Alpelisib | PIQRAY | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
50242-0092-01 | 50242-0092 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | No Longer Used | |
50242-0092-86 | 50242-0092 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | No Longer Used | |
50242-0094-47 | 50242-0094 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | In Use | |
50242-0094-90 | 50242-0094 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug. 15, 2019 | In Use | |
00004-1100-20 | 00004-1100 | Capecitabine | Xeloda | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 30, 1998 | In Use | |
00004-1100-75 | 00004-1100 | Capecitabine | Xeloda | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 30, 1998 | Dec. 31, 2014 | In Use |
00004-1101-50 | 00004-1101 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 30, 1998 | In Use | |
00004-1101-51 | 00004-1101 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 5, 2010 | Dec. 20, 2011 | In Use |
00004-1101-75 | 00004-1101 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | April 30, 1998 | Dec. 31, 2014 | In Use |
00078-0694-48 | 00078-0694 | ceritinib | ZYKADIA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | March 18, 2019 | In Use | |
00078-0694-84 | 00078-0694 | ceritinib | ZYKADIA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | March 18, 2019 | In Use | |
00409-1112-01 | 00409-1112 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Feb. 28, 2019 | In Use | |
00597-0137-30 | 00597-0137 | Afatinib | Gilotrif | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug. 9, 2013 | In Use | |
00597-0137-90 | 00597-0137 | Afatinib | Gilotrif | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct. 1, 2018 | In Use | |
00597-0138-30 | 00597-0138 | Afatinib | Gilotrif | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug. 8, 2013 | In Use | |
00597-0138-95 | 00597-0138 | Afatinib | Gilotrif | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug. 8, 2013 | In Use | |
14789-0600-10 | 14789-0600 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov. 19, 2018 | In Use | |
16714-0908-01 | 16714-0908 | Bleomycin | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Dec. 1, 2018 | In Use | |
16714-0886-01 | 16714-0886 | Bleomycin | Bleomycin | 15.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Dec. 1, 2018 | In Use | |
16714-0909-01 | 16714-0909 | Gemcitabine Hydrochloride | Gemcitabine | 200.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Nov. 1, 2018 | In Use | |
16714-0930-01 | 16714-0930 | GEMCITABINE HYDROCHLORIDE | GEMCITABINE | 1.0 g/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Nov. 1, 2018 | In Use | |
16729-0306-10 | 16729-0306 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan. 9, 2019 | In Use | |
44567-0530-01 | 44567-0530 | cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | April 5, 2019 | In Use | |
00019-9450-01 | 00019-9450 | Sodium Iodide I-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Aug. 22, 2011 | July 1, 2017 | No Longer Used |
00019-9450-02 | 00019-9450 | Sodium Iodide I-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Aug. 22, 2011 | July 1, 2017 | No Longer Used |
00019-9450-03 | 00019-9450 | Sodium Iodide I-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Aug. 22, 2011 | July 1, 2017 | No Longer Used |
00019-9450-04 | 00019-9450 | Sodium Iodide I-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Aug. 22, 2011 | July 1, 2017 | No Longer Used |
Found 10,000 results in 8 milliseconds — Export these results